FS Specialty Lending Fund Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts

	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023
Assets
Investments, at fair value
Non-controlled/unaffiliated Investments
Non-Controlled/Affiliated
Controlled/affiliated
Total investments, at fair value
Cash
Cash and cash equivalents
Restricted cash
Foreign currency, at fair value (cost—$350 and $0, respectively)
Receivable for investments sold and repaid
Interest receivable
Dividends receivable
Derivative Assets
Total Return Swap
Forward foreign currency exchange contracts
Total derivative Assets
Swap income receivable
Prepaid expenses and other assets
Total assets
Liabilities
Payable for investments purchased
Repurchase facility payable (net of deferred financing costs of $4,008 and $5,563, respectively)
Repurchase Facility
Credit Facilities
Total repurchase facility payable (net of deferred financing costs of $4,008 and $5,563, respectively)
Secured note payable, net of deferred financing costs
Unrealized depreciation on swap contracts
Total Return Swap
Total unrealized depreciation on swap contracts
Unrealized depreciation on forward foreign currency exchange contracts
Forward foreign currency exchange contracts
Total unrealized depreciation on forward foreign currency exchange contracts
Swap income payable
Shareholder distributions payable
Management fees payable
Administrative services expense payable
Interest payable
Trustees' fees payable
Other accrued expenses and liabilities
Total liabilities
Shareholders' equity
Preferred shares, $0.001 par value, 50,000,000 shares authorized, none issued and outstanding
Common shares, $0.001 par value, 700,000,000 shares authorized, 75,917,730 shares issued and outstanding(3)
Capital in excess of par value
Accumulated earnings (deficit)
Total shareholders' equity
Total liabilities and shareholders' equity
Net asset value per common share at period end (in USD per share)
Amortized Cost
Non-controlled/unaffiliated Investments
Non-Controlled/Affiliated
Controlled/affiliated
Total amortized Cost
Deferred financing cost on facilities payable
Repurchase Facility
Credit Facilities
Total deferred financing cost on facilities payable
Deferred financing costs on secured notes payable
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Preferred stock, par value (in USD per share)
Common stock, shares authorized
Common stock, shares issued

Comments